Letter to the Editor: Reconsidering the routine use of adjuvant somatostatin analogs in type I gastric neuroendocrine tumors after endoscopic treatment

doi:10.3748/wjg.120316

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 36

This Article

(0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article (XML)

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Sep 28, 2026; 32(36): 120316
Published online Sep 28, 2026. doi: 10.3748/wjg.120316

Letter to the Editor: Reconsidering the routine use of adjuvant somatostatin analogs in type I gastric neuroendocrine tumors after endoscopic treatment

Bengi Ozturk, Hatime Arzu Yasar

Bengi Ozturk, Department of Gastroenterology, Hacettepe University Faculty of Medicine, Ankara 06230, Türkiye

Hatime Arzu Yasar, Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara 06590, Türkiye

Author contributions: Ozturk B, Yasar HA contributed to the conception, drafting, and revision of the manuscript and approved the final version.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Corresponding author: Bengi Ozturk, MD, Assistant Professor, Department of Gastroenterology, Hacettepe University Faculty of Medicine, Tıp Fakultesi Street, Ankara 06230, Türkiye. drbengiozturk@gmail.com

Received: February 25, 2026
Revised: April 26, 2026
Accepted: June 4, 2026
Published online: September 28, 2026
Processing time: 178 Days and 8.9 Hours

Core Tip

Core Tip: Type I gastric neuroendocrine tumors are usually indolent and are associated with low metastatic potential. Although adjuvant somatostatin analog therapy following endoscopic resection can reduce recurrence risk, its routine use in low-risk patients should be carefully evaluated considering the scarce survival data and potential treatment-related adverse effects.